

Available online on 15.01.2016 at <http://jddtonline.info>**Journal of Drug Delivery and Therapeutics***An International Peer Reviewed Journal*

Open access to Pharmaceutical and Medical research

© 2016, publisher and licensee JDDT, This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited

## RESEARCH ARTICLE

**DEVELOPMENT AND OPTIMIZATION OF CHRONOPHARMACEUTICAL DRUG DELIVERY SYSTEM FOR ASTHMA**<sup>1</sup>Shilpa Praveen Chaudhari\*, <sup>1</sup>Pallavi M Chaudhari, <sup>2</sup>Sandeep Narawane<sup>1</sup>Dept. of Pharmaceutics, Padmashree Dr. D.Y. Patil College of Pharmacy, Akurdi, Pune-44, India<sup>2</sup>Marathwada Mitra Mandal's College of Pharmacy, Thergaon, Pune-33, India\*Corresponding Author's Email: [shilpapchaudhari78@yahoo.com](mailto:shilpapchaudhari78@yahoo.com)

Received 18 Nov 2015; Review Completed 08 Dec 2015; Accepted 12 Dec 2015, Available online 15 Jan 2016

**ABSTRACT**

The present research was designed to increase bioavailability and solubility of Montelukast Sodium by formulating Chronopharmaceutical delivery system. In the present study firstly immediate release core tablets were prepared by direct compression using Response Surface Methodology with different superdisintegrants, diluents and surfactants to release drug faster. In that formulation containing cross carmellose sodium and Poloxamer-188 with highly soluble lactose gave 95% release in 30 minutes with optimum pre & post compression characteristics. Chronopharmaceutical Drug delivery formulations were then prepared by press coating using polymers as Xanthan gum, Polyox, HPMC & Ethyl Cellulose alone and in combination. The results revealed that combinations of these polymers give better lag time rather than using a single polymer. Thus it can be concluded that combining hydrophilic and hydrophobic polymer can be done to achieve the respected lag time required for pulsatile release.

**Keywords:** Montelukast Sodium, Chronopharmaceutical Drug Delivery System.**1. INTRODUCTION**

Traditionally, drug delivery systems have focused on constant/sustained drug output with the objective of minimizing peaks and valleys of drug concentrations in the body to optimize drug efficacy and to reduce adverse effects. Diseases where a constant drug levels are not preferred, but needs a pulse of therapeutic concentration in a periodic manner acts as a push for the development of "Chronopharmaceutical Drug Delivery Systems"<sup>1-2</sup>. The Montelukast Sodium is Leukotriene receptor antagonist used for the maintenance treatment of asthma, chronic asthma attacks and to relive symptoms of seasonal allergies.

Asthma is chronic inflammatory disease of the airways, characterized by hyper responsiveness to variety of stimuli. The role of circadian rhythm in the pathogenesis and treatment of asthma indicates that airway resistance increases progressively at night in asthmatic patient. Circadian changes are seen in normal lung function, which reaches in low point in the early morning hours. The worsening of asthma at night, commonly referred to as Nocturnal Asthma (NA). A drug delivery system administered at bedtime but releasing drug during morning hours would be ideal in this case. Nocturnal Asthma is variable exacerbation of underlying asthma condition associated with increase in symptoms, need

for medication, airway responsiveness, and/or worsening of lung function<sup>4</sup>. Press coated tablets (PCTs) gained wide interest 'claiming some advantages over regular and (pan-) coated tablets, such as to protect hygroscopic, light-sensitive or oxygen-labile drugs from environmental-atmospheric ill effects or decomposition of acid-labile drugs by gastric fluids; to separate incompatible drugs from each other; to achieve a sustained release in that the drug in the core is embedded in waxes or fats constituting a depot; to protect the gastric mucosa from irritation by certain drugs by using enteric coating material in the outer press-coating granules; or to achieve intermittent release by incorporating one portion of drug in the core and the other in the coat, separated by a film-coat or a second press-coat drawbacks of the press-coating technique are the multistep processes involved, and the requirement for reliable and reproducible central positioning of the core tablet within press-coated tablet (PCT)<sup>5-8</sup>. The aim of the study was to develop and physico-chemically characterize pulsatile delivery tablet of Montelukast using different polymers. Montelukast has a biological half-life of about 2.5-5.5 hrs and 64 % bioavailability. Development of pulse release formulation of Montelukast can be advantageous, that can provide specific lag time and increase compliancy of the dosage form towards patient's side. Asthma peak is more in

early morning so it is not feasible to take tablet in midnight so pulsatile delivery is preferred one because this type of tablet should be taken after dinner which deliver drug immediately after a specified lag time about 4-5hrs. So drug may available (right time, right site) in blood circulation about 3 o'clock so it is available to protect from early morning asthma due to its 4-6 hrs. of half-life<sup>3</sup>.

So development of formulation consisted of a rapidly disintegrating core tablet press coated by a barrier layer consisting of varying concentrations of Xanthan Gum, Polyox303, Ethyl cellulose and Hydroxypropylmethyl cellulose. Ethylcellulose and hydrophilic polymers are used as a rate controlling polymer to achieve desired lag time.

### MATERIALS AND METHODS

Drug Montelukast Sodium was obtained as gift sample from Shreya pharmaceutical ltd. Chikalhana,

Aurangabad, Maharashtra, India. Poloxamer-188, Poloxamer-407, Crosscarmalose sodium, Microcrystalline Cellulose, Sodium Starch Glycolate, Lactose, HPMC, Ethyl Cellulose, Xanthan Gum, Polyox were obtained from Research Lab Fine Chem.

### Preparation of core tablets:

The inner-core tablets were prepared using direct compression to perform various release kinetics, depending upon the release mechanism involved. The composition of different formulations were prepared applying design expert software factorial design in which varying amounts of superdisintegrants, type of superdisintegrant, surfactant and diluents. Drug and the Excipients were homogeneously blended and subsequently compressed into tablet (6 mm Punch) using 12 station multi tooling rotary tablet punching machine. The levels for the formulation design were as given in table 1.

Table 1 Formulation variables and their levels for core tablet optimization.

Level	X <sub>1</sub> -Concentration of Surfactant (mg)	X <sub>2</sub> -Concentration of superdisintegrants (%)	X <sub>3</sub> - Type of Surfactant	X <sub>4</sub> - Type of superdisintegrants	X <sub>5</sub> -Type of Diluent
-1	-1	-1	Poloxamer 407 (-1)	CCS(-1)	MCC(-1)
+1	1	1	Poloxamer 188 (1)	SSG(1)	Lactose(1)
Dependent Variable		Y <sub>1</sub> - Drug release in 30minutes			
		Y <sub>2</sub> -Disintegration Time (DT)			

Table 2 summarizes the experimental runs, their factor combinations and the translation of the coded levels to the experimental units used in the study.

Table 2: Factor combinations as per the chosen experimental design

Batch code	X <sub>1</sub>	X <sub>2</sub>	X <sub>3</sub>	X <sub>4</sub>	X <sub>5</sub>
1	-1.000	-0.800	-1	-1	-1
2	1.000	-1.000	-1	1	1
3	0.210	-0.040	-1	-1	-1
4	-1.000	1.000	-1	-1	1
5	0.160	1.000	1	-1	-1
6	0.910	0.250	-1	1	1
7	-1.000	-1.000	1	1	1
8	1.000	1.000	1	1	1
9	-1.000	-1.000	1	1	1
10	0.210	-0.040	-1	1	-1
11	-1.000	1.000	-1	1	-1
12	1.000	-1.000	1	-1	-1
13	0.160	1.000	1	-1	-1
14	1.000	-1.000	1	-1	-1
15	0.910	0.250	-1	-1	1
16	-0.500	0.500	1	1	1

### Formulation of Press coated tablet:

Powder blend for press-coated tablet was prepared by dry blending together different compositions of the Ethyl cellulose, HPMC, Polyox WSR301, and Xanthan gum as shown in Table 3. These excipients were dry blended in

different weight compositions using surface response design in order to get suitable polymer composition. This composition was dry blended until uniformly blended mixture was obtained. This mixture was then used for the preparation of press – coated tablet using direct compression method (10mm punch).

Table 3: Formulation variables for press coated tablet optimization

Level	X <sub>1</sub> -Concentration of Ethyl Cellulose	X <sub>2</sub> -Concentration of polymer	X <sub>3</sub> -Type of Polymers
-1	0	50	HPMC(10000)
0	75	100	Xanthan gum(01000)
+1	150	150	Polyox (00100)
			HPMC+ Polyox(-1-1-1-1-1)
			HPMC+ Xanthan gum(00001)
			Polyox+ Xanthan gum(00010)
<b>Dependant Variables: Y- Lag Time</b>			

Table 4: Formulation of Press coated tablet

Formulation	Factor-1 Concentration of polymer	Factor-2 Concentration of Ethyl cellulose	Factor-3 Types of Polymer
1	-0.8	-0.83481	{ 0 0 1 0 0 }
2	-0.07	-0.06	{ 0 0 1 0 0 }
3	-1	0	{ 0 0 0 1 0 }
4	0.971953	-0.3	{ 0 0 1 0 0 }
5	0.960118	-0.35	{ 0 1 0 0 0 }
6	0	1	{ 0 0 0 1 0 }
7	-1	-1	{ -1 -1 -1 -1 -1 }
8	-0.55	0.56	{ -1 -1 -1 -1 -1 }
9	-0.83	-0.82	{ 0 1 0 0 0 }
10	0.53	-0.54863	{ -1 -1 -1 -1 -1 }
11	-1	1	{ 0 0 0 0 1 }
12	0	-1	{ 0 0 0 1 0 }
13	0.53	-0.54863	{ -1 -1 -1 -1 -1 }
14	-0.4	0.96767	{ 0 0 1 0 0 }
15	-0.55	-0.56	{ 0 0 0 0 1 }
16	0.95	-0.44	{ 1 0 0 0 0 }
17	-1	0.19	{ 0 1 0 0 0 }
18	0.71	0.84	{ 0 1 0 0 0 }
19	0.56	0.55	{ 0 0 0 0 1 }
20	1	1	{ -1 -1 -1 -1 -1 }
21	1	0.623881	{ 1 0 0 0 0 }
22	1	0	{ 0 0 0 1 0 }
23	0.56	0.55	{ 0 0 0 0 1 }
24	-0.36	0.98	{ 0 1 0 0 0 }
25	0.17	-1	{ 0 1 0 0 0 }
26	-0.55	-0.56	{ 0 0 0 0 1 }
27	-0.28	0.95	{ 1 0 0 0 0 }
28	-0.55	0.56	{ -1 -1 -1 -1 -1 }
29	1	-1	{ 0 0 0 0 1 }
30	-0.86	-0.79	{ 1 0 0 0 0 }
31	0.971953	-0.3	{ 0 0 1 0 0 }

#### Evaluation of press coated tablets

Core tablets and Press Coated Pulsatile Tablets were evaluated for following parameters as per their pharmacopoeial procedures.

**Hardness test:** It was determined using Monsanto hardness tester<sup>9-11</sup>.

**Friability test:** Ten tablets were initially weighed and transferred into Roche friabilator. The friabilator was operated at 25 rpm for 4 minutes<sup>9-11</sup>.

**Weight variation test:** Ten tablets were selected randomly from each formulation and weighed individually to check for weight variation<sup>9-11</sup>.

#### In vitro drug release studies:

##### (A) Core Tablets

The *in vitro* drug release from core tablets was carried out using USP paddle apparatus at 50 rpm and 37±0.5°C. Phosphate buffer (pH 6.8) was used as the dissolution medium. The samples were withdrawn at regular intervals and analyzed by UV spectrophotometer at 225nm for the presence of the drug. Dissolution tests were performed in triplicate<sup>9-11</sup>.

### (B) Press Coated Pulsatile Tablets

The *in vitro* drug release from coated tablets was carried out using USP paddle apparatus at 50 rpm. HCl (0.1 N) and phosphate buffer (pH 6.8) were used as the dissolution medium. Initially tablets were subjected to dissolution in 0.1 HCl for 2h and after that media were changed to phosphate buffer (pH 6.8). The samples were withdrawn at regular intervals and analyzed by UV spectrophotometer at 225 nm for the presence of the drug. Dissolution tests were performed in triplicate.

### RESULT & DISCUSSION:

#### Compatibility Studies

In order to investigate the possible interactions between Montelukast Sodium and polymers and/or diluents, FT-IR of Drug were carried out by using FTIR spectrophotometer (FTIR-8400S) as shown in Fig.1a, and b. FT-IR results proved that the drug was found to be compatible with excipients as wave numbers are almost similar for pure drug and also drug excipients mixture.




Figure 1a: IR spectrum of the Montelukast sodium Drug



Figure 1b: IR spectrum of A) Drug B) Drug+Sodium Starch Glycolate C) Drug+Cross Camallose Sodium D) Drug+Lactose E) Drug+Microcrystalline Cellulose.

#### Precompression Parameters of Core Tablet Powder Blend

Bulk density, tapped density, Hausner's ratio and carr's index given in the Table 5. The angle of repose ( $\theta$ ) for all the formulations ranged from 19 to 25° indicating good flow properties. The result of compressibility index was between 12 to 16, which indicates good flow properties & for Hausners ratio was near/less about 1.2 also supported the results of free flowing.

#### Postcompression Parameters of Core Tablets

The tablet hardness, friability, weight variation of all tablet formulations were found to be satisfactory and reproducible as observed from the data in Table 6. The hardness of all the tablets was between 3 to 5 kg/cm<sup>2</sup>. In the present study, the loss in total weight in friability test was in the range of 0.77 to 0.91% that indicates, the percentage friability for all the formulations was found below 1% indicating that friability (%) is within the acceptable limits. In weight variation test, the pharmacopoeia limit for the percentage deviation for tablets weighing more than 50 mg is  $\pm 7.5\%$ . The average percentage deviation of all tablet formulations was found to be within limit, and hence all formulations passed the test for uniformity of weight as per official requirement.

Table5: Evaluation of directly compressible blends of core tablet

Formulations	Bulk Density(g/cm <sup>3</sup> )	Tapped Density(g/cm <sup>3</sup> )	Angle of Repose( <sup>0</sup> )	Carrs index (%)	Hausners ratio (HR)
F1	0.48	0.50	25.066	19.0	1.19
F2	0.55	0.60	21.65	16.6	1.20
F3	0.45	0.55	19.50	10.0	1.11
F4	0.55	0.66	21.03	16.6	1.20
F5	0.49	0.55	18.25	23.63	1.30
F6	0.50	0.60	19.9	16.6	1.20
F7	0.62	0.65	21.41	4.6	1.02
F8	0.50	0.55	19.69	18.0	1.21
F9	0.62	0.65	18.41	4.6	1.02
F10	0.45	0.48	22.50	10.0	1.11
F11	0.50	0.60	21.74	16.6	1.20
F12	0.45	0.50	19.13	18.0	1.21
F13	0.50	0.55	18.25	23.63	1.30
F14	0.45	0.50	22.13	18.0	1.21
F15	0.50	0.60	25.90	16.6	1.20
F16	0.45	0.50	27.74	18.0	1.21

Table 6: Evaluation of Formulations of rapid release core tablet

	Hardness(kg/c <sup>2</sup> ) (n=3)	Thickness(mm) (n=3)	Diameter (mm)	Weight variation(%)(n=20)	Disintegration time (Sec.)	Friability (%) (n=10)
F1	3.5±0.50	2.64±0.012	6.01±0.015	101±0.67	150	0.78
F2	4± 0.50	2.54±0.005	6.00±0.010	100±0.54	21	0.66
F3	5±0.50	2.60±0.010	6.02±0.007	102±0.66	180	0.62
F4	3±0.50	2.52±0.014	6.00±0.015	100±0.57	18	0.87
F5	3±0.50	2.65±0.009	6.01±0.009	100±0.88	105	0.85
F6	3±0.50	2.55±0.010	6.01±0.015	101±0.85	22	0.80
F7	4±0.50	2.57±0.012	6.03±0.017	99±1.15	24	0.78
F8	5±0.50	2.39±0.019	6.02±0.013	101±0.75	25	0.67
F9	4±0.50	2.5±0.020	6.02±0.012	98±1.3	24	0.71
F10	3±0.50	2.59±0.018	6.00±0.014	99±1.1	180	0.69
F11	3±0.50	2.69±0.019	6.01±0.009	99±1.2	210	0.81
F12	4±0.50	2.60±0.017	6.02±0.015	103±0.75	255	0.77
F13	5±0.50	2.504±18	6.03±0.015	101±0.60	105	0.62
F14	4±0.50	2.58±0.015	6.01±0.008	103±0.54	255	0.70
F15	4±0.50	2.61±0.012	6.03±0.018	103±0.56	22	0.82
F16	5±0.50	2.67±0.013	6.02±0.015	99±1.2	31	0.84

### In-Vitro Drug Release of core tablet

For preparation of immediate release core tablets different superdisintegrants were used. In that Poloxomer-407 containing formulation shows immediate & more release compared to other formulations. F4 formulation showed 95.49% drug

release in 30 minas observed in Figure 2a. The result shows that lactose with superdisintegrants shows good disintegration & dissolution properties as Lactose is highly water soluble & along with superdisintegrants the release was very fast. Whereas in spray dried mucilage-lactose, might have increased the viscosity & could have acted as barrier for diffusion & faster dissolution.




Figure 2a: Percent Drug Release of core tablets

The response surface graph figure 2b shows that as the conc. of superdisintegrants and conc. of surfactant increases % drug release decreased. While with increase in superdisintegrant and decrease in surfactant conc

increases the drug release. This might be due to high conc of surfactant drug may be entrapped in surfactant micelles.




Figure 2b: Effect of superdisintegrants and surfactant on drug Release

**Postcompression Parameters of Press-Coated Tablets**

The tablet hardness, friability, weight variation of all tablet formulations were found to be satisfactory and reproducible as observed from the data in Table 7. The hardness of all the tablets was between 7 and 8 kg/cm<sup>2</sup>. In the present study, the loss in total weight in friability test was in the range of 0.66 to 0.99% that indicates, the percentage friability for all the formulations was found

below 1% indicating that friability (%) is within the acceptable limits. In a weight variation test, the pharmacopoeia limit for the percentage deviation for tablets weighing more than 100mg is ±5%. The average percentage deviation of all tablet formulations was found to be within limit, and hence all formulations passed the test for uniformity of weight as per official requirement.



Table 7: Post-Compression Parameters for Press-Coated Tablets

Formulations	Hardness (Kg/cm <sup>2</sup> ) (n=3)	Thickness (mm)(n=3)	Diameter (mm)(n=3)	Weight Variation (%) (n=20)	Friability (%) (n=10)
F1	7±0.40	6.17±0.027	10.01±0.01	122.39±1.2	0.92
F2	7.5±0.27	5.89±0.15	10.00±0.02	217±1.4	0.86
F3	7±0.63	5.93±0.26	10.01±0.02	175±1.1	0.73
F4	7±0.28	6.09±0.27	10.02±0.02	251.1±1.1	0.77
F5	7.5±0.13	5.97±0.15	10.01±0.01	246.17±1.7	0.73
F6	8±0.45	5.95±0.26	10.00±0.02	300±2	0.68
F7	8±0.29	6.13±0.17	10.00±0.002	100±1.5	0.93
F8	7±0.28	6.02±0.15	10.01±0.01	239.5±1.4	0.88
F9	7±0.50	5.89±0.15	10.01±0.01	122±1.1	0.69
F10	7±0.40	5.93±0.26	10.00±0.02	210.35±1.1	0.82
F11	7.5±0.27	6.09±0.27	10.00±0.002	250±1.1	0.92
F12	7±0.63	5.97±0.15	10.01±0.01	150±1.4	0.77
F13	7±0.40	5.93±0.26	10.00±0.02	210.35±1.1	0.82
F14	7.5±0.13	6.13±0.17	10.01±0.02	277.58±1.2	0.81
F15	8±0.45	6.02±0.15	10.02±0.02	155.5±1.2	0.92
F16	8±0.29	5.97±0.15	10.01±0.01	239.5±1.3	0.97
F17	7±0.28	6.09±0.27	10.00±0.02	189.25±1.3	0.96
F18	7±0.50	5.97±0.15	10.00±0.002	323.5±1.1	0.72
F19	7±0.40	5.95±0.26	10.01±0.01	294.25±1.6	0.67
F20	7.5±0.27	6.13±0.17	10.01±0.01	350±1.8	0.69
F21	7±0.63	6.02±0.15	10.00±0.02	321.79±1.4	0.79
F22	7±0.28	5.93±0.26	10.00±0.002	275±1.1	0.88
F23	7±0.40	5.95±0.26	10.01±0.01	294.25±1.6	0.67
F24	8±0.45	5.97±0.15	10.00±0.002	280±2.0	0.69
F25	8±0.29	5.95±0.26	10.01±0.01	158.5±1.9	0.92
F26	8±0.45	6.02±0.15	10.02±0.02	155.5±1.2	0.92
F27	7±0.50	6.02±0.15	10.01±0.02	282.25±1.0	0.90
F28	7±0.28	6.02±0.15	10.01±0.01	239.5±1.4	0.88
F29	7.5±0.27	5.93±0.26	10.01±0.01	200±1.5	0.86
F30	7±0.63	6.09±0.27	10.00±0.02	22.75±1.4	0.87
F31	7±0.28	5.95±0.26	10.00±0.002	251.1±1.1	0.99

The percent release of drug for all tablet formulations was found to be satisfactory and reproducible.




Figure 3a: Percent drug release of coated formulations % Drug Release of coated formulations (Ethyl Cellulose and Polyox)




Figure 3b: Percent drug release of coated formulations (Ethyl Cellulose and Xanthan gum)




Figure 3c: Percent drug release of coated formulations (Ethyl Cellulose and HPMC)




Figure 3d: Percent drug release of coated formulations (Ethyl Cellulose and Polyox+ Xanthan gum)




Figure 3e: Percent drug release of coated formulations (Ethyl Cellulose and Xanthan gum+ HPMC)






Figure 3f: Percent drug release of coated formulations (Ethyl Cellulose and HPMC+Polyox)

#### Drug Release of coated formulations:-

Lag time is the important criteria to deliver drug. In following formulations different polymers in different concentration were used. The coated tablet formulation consisting of ethyl cellulose and Polyox, ethyl cellulose and xanthum gum, ethyl cellulose and HPMC achieved maximum 140 minutes, 175 minutes and 165 minutes maximum lag time respectively (figure (3a,3b,3c)). While the combination formulation consisting of ethyl cellulose, Polyox and xanthum gum, ethyl cellulose, xanthum gum and HPMC and ethyl cellulose, HPMC and Polyox achieved maximum 210 minutes, 170 minutes and 165 minutes Lag time respectively (Figure 3d,,3e,3f)). In this F12 formulation containing Xanthum gum, Polyox and ethyl cellulose combination showed the exact sigmoid curve and maximum lag time. Ethyl

cellulose is hydrophobic in nature and Xanthum gum as per literature is known to prolong the drug release when it is combined with Polyox a water soluble high molecular weight resin the lag time is prolonged for longer period of time.

#### CONCLUSION

Chronopharmaceutical Drug delivery formulations were prepared by direct compression press coating using Response Surface Methodology with polymers as Xanthum gum, Polyox, HPMC & Ethyl Cellulose alone and in combination. Polyox having a property of fast hydration & swelling useful for maintaining lag time. Xanthum gum has more viscosity on coming in contact with solvent and ethyl cellulose a hydrophobic polymer. So, combinations of these polymers give better lag time.

#### REFERENCES

- Jha N, Bapat S. Chronobiology and chronotherapeutics. *Kathmandu University Medical Journal* 2004; 2(8): 384-388.
- Botti B, Youan C: Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery. *J. Control. Rel.* 2004; 98(3): 337-353.
- <http://www.rxlist.com/singulair-drug/clinical-pharmacology.htm>
- Janugade B. U, Patil S. S., Patil S. V., Lade P. D., Formulation And Evaluation Of Press-Coated Montelukast Sodium Tablets For Pulsatile Drug Delivery System. *International Journal of Chemtech Research.* 2009;1(3): 690-691.
- Karavas E, Georgarakis E, Bikiaris D. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. *Eur J Pharm. Biopharma* 2006; (64): 115-26.
- Lu MF, Woodward L, Borodkin S. Xanthum gum and alginate based controlled release theophylline formulation. *Drug Dev Ind Pharm* 1991; 17(14): 1987-04.
- Neeraj Singh, Nisha, Vivek Gill, Parina Gill, Sukhbir Singh, *International Research Journal of Pharmaceutical and Applied Sciences* 2013; 3(4):84-87.
- Rajalakshmi R, Aruna U, Vinesha V, Vardhan RV, Ramesh DR. Pulsatile drug delivery system: a novel approach for chronopharmacological disorders. *IAJPR.* 2013; 3(7): 5150-5162.
- Lachman Leon, Lieberman Herbert A.; *Pharmaceutical Dosage Forms: Tablets.* In: *The theory and Practice of Industrial Pharmacy;* Lea and Febiger, U.S.A.; 3rd Edition; 1991, 293-345.
- Lieberman H.A, Lachman L, Schwartz J. B. *Pharmaceutical Dosage Forms: Tablets.* 1990; Vol 1, 131-188.
- Lieberman H. A, Lachman L, Schwartz J. B. *Pharmaceutical Dosage Forms: Tablet.* 1990; vol.- II, 2nd edition 1-104, 201-338.